The global Gastroesophageal Junction Adenocarcinoma Therapeutics market garnered a market value of USD 5.55 Billion in 2022 and is expected to accumulate a market value of USD 34.3 Billion by registering a CAGR of 18% in the forecast period 2023 to 2033.
Growth of the Gastroesophageal Junction Adenocarcinoma Therapeutics market can be attributed to increasing prevalence, awareness and development in therapies to treat the ailment. The market for Gastroesophageal Junction Adenocarcinoma Therapeutics registered a CAGR of 11% in the historical period 2018 to 2022
Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach. It is a relatively rare cancer, but its incidence has been increasing in recent years.
Gastroesophageal Junction Adenocarcinoma therapeutics refers to the treatments and drugs that are used to manage this type of cancer. The treatment approach for GEJAC depends on various factors, including the stage of cancer, the location of the tumor, and the overall health of the patient.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 6.55 Billion |
| Anticipated Forecast Value (2033) | USD 34.3 Billion |
| Projected Growth Rate (2023 to 2033) | 18% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Gastroesophageal Junction Adenocarcinoma Therapeutics reflected a value of 11% during the historical period, 2018 to 2022.
The growth of the GEJAC therapeutics market during this period was attributed to several factors, including the increasing incidence of GEJAC, rising demand for effective cancer therapies, and the development of new treatment options. In addition, the market was also driven by increasing government initiatives and funding for cancer research.
Overall, the GEJAC therapeutics market has been growing steadily in the past few years, and this trend is expected to continue in the coming years as new and more effective treatment options become available.
Thus, the market for Gastroesophageal Junction Adenocarcinoma Therapeutics is expected to register a CAGR of 18% in the forecast period 2023 to 2033.
Growing awareness among patients and healthcare professionals driving market growth for GEJAC market
The incidence of GEJAC has been increasing in recent years, which is driving demand for effective cancer therapies. There have been significant advancements in GEJAC therapeutics, including the development of new drugs, targeted therapies, and immunotherapies. These new treatment options are more effective and have fewer side effects compared to traditional chemotherapy.
Governments around the world are investing in cancer research and providing funding for clinical trials, which is driving the development of new and innovative GEJAC therapeutics. There is a growing awareness among patients and healthcare professionals about GEJAC, which is leading to earlier detection and diagnosis, and ultimately, better outcomes for patients.
There is a growing demand for personalized medicine, which involves tailoring treatment to an individual's genetic makeup and disease characteristics. This approach is particularly relevant for GEJAC, which is a complex and heterogeneous disease.
Availability of therapeutic treatments shaping landscape for GEJAC market
Surgery: Surgery is often used to remove the tumor and surrounding tissues. The type of surgery depends on the location and size of the tumor, and may include esophagectomy, gastrectomy, or both.
Radiation therapy: Radiation therapy uses high-energy radiation to kill cancer cells. It may be used alone or in combination with chemotherapy, and is often used to treat GEJAC that has spread to nearby lymph nodes or organs.
Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. It may be used alone or in combination with radiation therapy or surgery. Common chemotherapy drugs used for GEJAC include cisplatin, 5-fluorouracil, and docetaxel.
Targeted therapy: Targeted therapy involves the use of drugs that target specific molecules involved in cancer growth and spread. For GEJAC, targeted therapies that may be used include trastuzumab, ramucirumab, and pembrolizumab.
Immunotherapy: Immunotherapy works by helping the body's immune system to recognize and attack cancer cells. It is a relatively new treatment approach for GEJAC, but has shown promise in clinical trials.
Principal Consultant
Lack of effective treatment options derailing progress of GEJAC market
The cost of cancer treatment, including GEJAC, is often high and can be a barrier for many patients, particularly those without adequate insurance coverage or financial resources. Cancer treatments such as chemotherapy and radiation therapy can cause significant side effects, such as nausea, vomiting, hair loss, and fatigue, which can impact patients' quality of life.
Despite advancements in GEJAC therapeutics, there is still a lack of effective treatment options for some patients, particularly those with advanced or metastatic disease. Some patients with GEJAC may develop resistance to chemotherapy or targeted therapies, making treatment less effective over time.
GEJAC is a relatively rare cancer, and there may be limited awareness among patients and healthcare professionals about its diagnosis and treatment. The development of new GEJAC therapeutics can be a lengthy and costly process, with regulatory challenges such as clinical trial requirements and approval processes posing additional barriers.
Presence of key players spurring growth of GEJAC therapeutics in North America
The North America Gastroesophageal Junction Adenocarcinoma (GEJAC) therapeutics market is one of the largest in the world, driven by a high incidence of GEJAC in the region. In the United States, for example, GEJAC is one of the fastest-growing cancers, with an estimated 18,440 new cases diagnosed in 2021.
The market is dominated by several major pharmaceutical companies, including Bristol-Myers Squibb, Merck & Co., and Eli Lilly and Company, among others, who offer a range of treatment options for GEJAC, including chemotherapy, targeted therapies, and immunotherapy.
In recent years, there has been a growing focus on the development of novel immunotherapies for GEJAC, particularly those targeting immune checkpoint inhibitors such as PD-1 and PD-L1. In 2021, the FDA approved pembrolizumab for the treatment of certain patients with GEJAC, marking a significant advance in the field. Thus, North America is expected to possess 44% market share for GEJAC market in 2023.
Rise in number of people suffering from GEJAC bolstering market growth in Europe
The Europe Gastroesophageal Junction Adenocarcinoma (GEJAC) therapeutics market is one of the largest in the world, with a significant number of new cases diagnosed each year. According to the European Cancer Information System, there were approximately 98,800 new cases of esophageal cancer, including GEJAC, in Europe in 2020.
The market is dominated by several major pharmaceutical companies, including Roche, AstraZeneca, Merck & Co., and Bristol-Myers Squibb, among others, who offer a range of treatment options for GEJAC, including chemotherapy, targeted therapies, and immunotherapy.
In recent years, there has been a growing focus on the development of novel immunotherapies for GEJAC, particularly those targeting immune checkpoint inhibitors such as PD-1 and PD-L1. In 2020, the European Commission approved pembrolizumab for the treatment of certain patients with GEJAC, marking a significant advance in the field. Thus, Europe is expected to possess 37% market share for GEJAC market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Early-stage GEJAC maximizing use of surgeries for treatment
In general, surgery is one of the primary options for treating Gastroesophageal Junction Adenocarcinoma. For early-stage Gastroesophageal Junction Adenocarcinoma, surgery is often the preferred treatment option.
This may involve removing part or all of the esophagus and the upper part of the stomach, followed by reconstructing the digestive tract. Surgery can also be used in conjunction with other treatments, such as chemotherapy or radiation therapy. Thus, by treatment, Esophagectomy surgery is expected to possess 40% market share for GEJAC market in 2023.
Key players in the Gastroesophageal Junction Adenocarcinoma Therapeutics market are Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte, Macrogenics, Merck Co, Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 6.55 Billion |
| Market Value in 2033 | USD 34.3 Billion |
| Growth Rate | CAGR of 18% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug, Diagnosis, Treatment, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Astellas Pharmaceuticals; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daichii Sankyo; Elevar Therapeutics; Eli Lilly; FivePrime Therapeutics; Incyte; Macrogenics; Merck Co; Ono Pharmaceuticals; Roche; Taiho Pharmaceuticals; Zai Labs; ZymeWorks |
| Customization | Available Upon Request |
From 2018 to 2022, the Gastroesophageal Junction Adenocarcinoma Therapeutics market grew at a CAGR of 11%
The global Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to grow with an 18% CAGR during 2023 to 2033.
As of 2033, the Gastroesophageal Junction Adenocarcinoma Therapeutics market is expected to reach USD 34.3 Billion
Esophagectomy surgery is expected to hold 40% of the market share in 2023 for Gastroesophageal Junction Adenocarcinoma Therapeutics market.
North America is expected to possess 44% market share for Gastroesophageal Junction Adenocarcinoma Therapeutics market in 2023.
Europe Gastroesophageal Junction Adenocarcinoma Therapeutics market size is expected to possess 37% market share in 2023.
1. Executive Summary | Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 5.1. Trastuzumab 5.2. Ramucirumab 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Endoscopy 6.2. X-ray 6.3. CT Scan 6.4. PET Scan 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Esophagectomy surgery 7.2. Esophageal dilation 7.3. Chemotherapy 7.4. Targeted therapy 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Hospital Pharmacy 8.2. Retail Pharmacy 8.3. Online Pharmacy 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Astellas Pharmaceuticals 19.2. AstraZeneca 19.3. Bayer 19.4. Beigene 19.5. Bristol-Myers Squibb 19.6. Daichii Sankyo 19.7. Elevar Therapeutics 19.8. Eli Lilly 19.9. FivePrime Therapeutics 19.10. Incyte 19.11. Macrogenics 19.12. Merck Co 19.13. Ono Pharmaceuticals 19.14. Roche 19.15. Taiho Pharmaceuticals 19.16. Zai Labs 19.17. ZymeWorks 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Gastroesophageal Junction Adenocarcinoma Therapeutics Market
